Precision Biosystems, LLC
Precision Biosystems is a Massachusetts-based company that develops and manufactures BlotCycler, an automated western blot processing system. The system is based on patented fluid distribution technology. The overarching goal of BlotCycler is help you automate the traditional manual western blot processing during the immunodetection step.
LX Medical Corporation
LX Medical Corporation is an early stage Massachusetts Corporation commercializing a suite of endobronchial imaging probes and image-guided bronchoscopic tools that will be used by interventional pulmonologists and thoracic surgeons to improve outcomes in diagnostic and therapeutic medical procedures for several lung diseases. A primary focus for the company is addressing unmet needs in lung cancer diagnosis and treatment.
Innovo Bioanalysis develop innovative bioanalytical methodology and technology using advanced mass spectrometry to identify biomarkers in diseases with unknown mechanism in unmet medical needs. The company also offers contract bioanalytical research service for bioanalysis of biomarkers, drug and metabolites in biological samples to address pharmacokinetics (PK), pharmacodynamics (PD), drug metabolism (DM), and toxicokinetics (TK) in drug discovery and development.
Manna Molecular Science
Manna Molecular Science has identified a medically sound, lab-tested system delivering whole-plant cannabinoids directly to those who need them most. Massachusetts-based team of developers are revolutionizing the cannabis industry, designing scalable product production using new age robotic equipment. Manna Molecular Science's flagship cannabis transdermal patch is the first cannabis optimized patch that has been developed by real pharmaceutical scientists from MIT and Genzyme using state-of-the-art product design and research methods. It works for all cannabinoids, and is meant to work with high quality whole-plant cannabis extracts that are then printed on each patch with pharmaceutical quality. MannaBot One is a custom-engineered 3D printer for the manufacturing of transdermal patches, giving us both precision control and scale volume fabrication.
X2C BioSciences is an early stage life sciences and biopharmaceutical company committed to addressing the incessantly evolving unmet needs in oncology, arising from the remarkable progress being made in our understanding of the molecular mechanisms underlying cancer in recent years. The current mission of the company is focused on developing and commercializing dependable, next-generation, minimally invasive diagnostic & prognostic approaches and more effective & comprehensive therapeutic strategies, for various solid tumors.
tBrexa BioSciences Inc.(tBrexa), is a privately held early stage, preclinical biopharmaceutical company focused on the discovery, development, and commercialization of therapies that will transform the treatment of cancer. The current treatments such as surgery, radiation, and chemotherapy have limited therapeutic effects and significant undesirable side effects. tBrexa is developing a novel product that will result in fewer non-specific side-effects and a healthier treatment. tBrexa is working on changing the way we approach cancer, one patient at a time.
Hilltop Biosciences is helping animals heal faster, stronger. Using next generation allogeneic tissue, we make it easier to treat soft tissue injuries. Our pharma-free products up-regulate the bodies own immune response to regenerate tissue quickly.
YPB is a Brand Protection and Customer Engagement solutions Company. Amongst other products, YPB manufactures small, secure and ultra low-cost chemical microbarcodes for anti-counterfeiting. In addition, YPB provides Security Packaging and Anti-Theft solutions, Consulting Services and YPB’s proprietary CONNECT platform enables clients to PROTECT their high-value brands and Vital Documents from the risks of counterfeit, product diversion and theft, while providing the tools to CONNECT directly with their customers. YPB is expanding its global footprint with an established presence in Australia, China, Thailand, USA, Mexico and India.
Latrax is developing a novel device for the Vagus Neuronal Therapy (VNS) an adjunctive therapy in reducing seizure frequency in adults and adolescents over age of 12 with partial-onset seizure that are refractory to anti epileptic drugs